Feldene's first full year sales
Executive Summary
Pfizer's one-a-day nonsteroidal anti-inflammatory had U.S. retail sales of $124 mil. (at acquisition cost) in its first 12 months on the market, according to Pharmaceutical Data Services' (PDS) data. PDS' first year retail sales projection for Glaxo's Zantac in the U.S. was $110 mil., putting Feldene ahead of the anti-ulcer agent in first year sales performance. Based on information from another source, "The Pink Sheet" put Feldene first year sales at $109 mil. (July 30, T&G-1).